Theoretically, for those aggressive ABC-DLBCL cases homogenously expressing unstable Blimp-1 mutants13, 19, 44, 54, bortezomib not only inhibits NF-κb activity but also stabilizes the unstable Blimp-1 mutants in ABC-DLBCL cells. The gene discussed is PRDM1; the disease is diffuse large B-cell lymphoma.